Kelun-Biotech’s Dual-Load ADC Drug SKB565 Approved for Clinical Trials in Advanced Solid Tumors
The controlled subsidiary Kelun-Biotech has received a clinical trial notice from the National Medical Products Administration’s Center for Drug Evaluation, approving its investigational new drug application for the novel dual-load ADC drug SKB565, for the treatment of advanced solid tumors. The drug is the first dual-load antibody-drug conjugate (ADC) from Kelun-Biotech to enter the clinical stage.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Biotechnology, with intensity 60/100 and 75% confidence over a long term horizon.
Healthcare · 13.3
Biotechnology
- Direction
- positive
- Intensity
- 60
- Confidence
- 75%
- Horizon
- Long term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 50
- Confidence
- 70%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.